Here are the editors' top picks for the week ended Feb. 23.
Hospitals face off against drugmakers as Congress targets charity care program
President Donald Trump's proposal to reform 340B drug discounts for nonprofit hospitals was the latest salvo in a brewing battle expected to soon come to a head in a House committee.
White House blames Medicare, Medicaid for driving up drug prices
Government policies and programs like Medicare and Medicaid are dampening competition and artificially driving up the prices of prescription medicines, the White House argued in a new report.
Merck's cancer deal turns up heat in high-stakes immunotherapy market
With its nearly $400 million acquisition, U.S. drugmaker Merck & Co. Inc. is creating possibilities for combinations in a competitive class of cancer therapies, a week after rival Bristol-Myers Squibb Co. made its own deal.
Indian regulator signals it may let US stent companies exit market
India's National Pharmaceutical Pricing Authority said in a statement that it will "not disallow" applications by overseas stent manufacturers to withdraw their products.
US tax code revamp dampens Q4'17 healthcare results, adds M&A firepower for 2018
Results for 2017's final quarter were laden with one-time charges as healthcare companies paid the price for a U.S. law that will lower their tax rates in 2018 and beyond.
Trump administration makes way for cheaper but riskier health plans
The Trump administration unveiled two new proposed rules that would expand short-term health plans from the current three-month limit to a full year. The plans are intended to be cheaper options, but lack certain protections.
Teva insists on 'better days,' sees Buffett boost
Teva Pharmaceutical Industries Ltd. received a vote of confidence from billionaire investor Warren Buffett, whose Berkshire Hathaway bought $357.7 million in the drugmaker's U.S. listed stock.
Capitol Checkup: Drug cost-sharing; Merck CEO on Trump split; kid flu deaths up
A panel of experts debated the knotty challenges of lowering Americans' cost-sharing on drugs; Merck's CEO gave more details about why he exited a White House council, triggering an exodus of corporate leaders; and 22 more children died of the flu.